Data updated: Jun 28, 2026
Muscle Spasm Clinical Trial Landscape
Muscle Spasm is being studied across 95 clinical trials registered since 2008, with 10 programs currently active. The competitive pipeline includes 5 active Phase 3 trials, 3 active Phase 2 trials, and 1 active Phase 1 trials.
Top industry sponsors include Chongqing Claruvis Pharmaceutical Co., Ltd., Ipsen, Merz Pharmaceuticals GmbH.
Trial activity
10 active / 95 total since 2008
Active by phase 5 Ph3 / 46 3 Ph2 / 21 1 Ph1 / 9 1 Ph4 / 19
Sponsor activity
Who is running trials now — green active, blue completed, red failed/terminated.
Sorted by active Active Done Failed
Chongqing Claruvis Pharmaceutical Co., Ltd. 2 0 0
Ipsen 1 7 1
Merz Pharmaceuticals GmbH 1 6 0
RVL Pharmaceuticals, Inc. 1 4 0
Elpida Therapeutics SPC 1 0 0
AbbVie 0 5 3
Medy-Tox 0 6 0
Sun Pharma Advanced Research Company Limited 0 3 0
How the field has grown
New-trial starts peaked in 2017 (5 registered); 2025 saw 0. The right-hand chart shows median Phase 3 enrollment by start year — the number in parentheses is that year's Phase 3 trial count (14 in total), so single-trial years (and years with no Phase 3 starts) are obvious. Both are by trial start date; the current year is partial.
New trials started by year
2016 4
2017 5
2018 4
2019 3
2020 3
2021 4
2022 2
2023 5
2024 4
2025 0
2026 5
TheraRadar.com
Median Phase 3 enrollment by start year
2016 (0) 0
2017 (2) 172
2018 (2) 430
2019 (2) 322
2020 (1) 1,004
2021 (1) 32
2022 (1) 198
2023 (1) 12
2024 (2) 195
2025 (0) 0
2026 (2) 254
TheraRadar.com
Full trial pipeline
Every active and completed trial across Phase 1–4, with enrollment analytics. Sortable, filterable, exportable with Pro.
NCT03992404 ACTIVE NOT RECRUITING
Study to Compare the Efficacy and Safety of NT 201 (Botulinum Toxin) With Placebo for the Treatment of Lower Limb Spasticity Caused by Stroke or Traumatic Brain Injury
Merz Pharmaceuticals GmbH n=603
NCT07478822 RECRUITING
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd. n=300
NCT06783114 RECRUITING
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
Chongqing Claruvis Pharmaceutical Co., Ltd. n=254
NCT05179577 NOT YET RECRUITING
A Study to Investigate Arbaclofen ER Tablets for the Treatment of Spasticity in Patients With Multiple Sclerosis
RVL Pharmaceuticals, Inc. n=442
NCT07242300 NOT YET RECRUITING
Efficacy and Safety of Recombinant Botulinum Toxin Type A (Eveotox) for Injection in the Treatment of Adult Upper Limb Spasticity .
JHM BioPharma (Tonghua) Co. , Ltd. n=207
NCT06536751 COMPLETED
Therapeutic Photobiomodulation and Tretament of Spasticity
University of Nove de Julho n=12
NCT06863662 COMPLETED
Efficacy and Safety of Etoricoxib/Tizanidine Versus Etoricoxib for Acute Low Back Pain Associated to Muscle Spasm
Laboratorios Silanes S.A. de C.V. n=136
NCT05289921 COMPLETED
To Evaluate HU-014 in the Treatment of Post Stroke Upper Limb
Huons Co., Ltd. n=198
NCT00681538 COMPLETED
A Study of the Safety and Effectiveness of Sativex®, for the Relief of Symptoms of Spasticity in Subjects, From Phase B, With Multiple Sclerosis (MS)
Jazz Pharmaceuticals n=572
NCT04815967 TERMINATED
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Upper Limb Spasticity
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC n=32
NCT02106351 COMPLETED
Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children
Ipsen n=212
NCT01682148 TERMINATED
Comparing Lower-concentration Dysport Treatment Targeted to the Neuromuscular Junction With Current Clinical Practice
Ipsen n=100
NCT03319732 COMPLETED
A Study to Evaluate the Long-term Safety of Arbaclofen Extended-Release Tablets for Patients With Spasticity Due to MS
RVL Pharmaceuticals, Inc. n=323
NCT03290131 COMPLETED
A Study to Investigate the Safety and Effectiveness of Arbaclofen Extended-Release Tablets for Patients With MS
RVL Pharmaceuticals, Inc. n=536
NCT01844232 COMPLETED
One Year, Open Label, Dose Escalation Long-term Safety Study in Multiple Sclerosis (MS) Subjects With Spasticity
RVL Pharmaceuticals, Inc. n=150
NCT01743651 COMPLETED
Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis
RVL Pharmaceuticals, Inc. n=353
NCT04671082 COMPLETED
Efficacy and Safety of Tolperisone in Subjects With Pain Due to Acute Back Muscle Spasm
Neurana Pharmaceuticals, Inc. n=1,004
NCT03289702 COMPLETED
CORETOX® in Treatment of Post Stroke Upper Limb Spasticity (Phase3)
Medy-Tox n=220
NCT01893411 COMPLETED
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Leg(s) in Cerebral Palsy
Merz Pharmaceuticals GmbH n=311
NCT02002884 COMPLETED
Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy
Merz Pharmaceuticals GmbH n=351
NCT03261167 COMPLETED
A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity
GlaxoSmithKline n=124
NCT01457352 COMPLETED
Efficacy and Safety of SPARC0921 in Subjects With Spasticity
Sun Pharma Advanced Research Company Limited n=392
NCT01520545 COMPLETED
Safety Study of 3 mg/mL Baclofen Injection (Intrathecal) Using A Programmable Pump
Piramal Critical Care, Ltd. n=153
NCT01313767 COMPLETED
MEDITOXIN® Versus BOTOX® in the Treatment of Post-stroke Spasticity of the Upper Limb Spasticity
Medy-Tox n=196
NCT01905683 COMPLETED
Long-term Open-label Study of Botulinumtoxin Type A to Treat Spasticity of Leg(s) or Leg(s) and Arm in Cerebral Palsy
Merz Pharmaceuticals GmbH n=370
NCT01603459 COMPLETED
Efficacy and Safety Dose Titration Study of Botulinum Toxin Type A to Treat Spasticity in the Leg and Arm
Merz Pharmaceuticals GmbH n=155
NCT02145676 TERMINATED
OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Allergan n=53
NCT01205451 COMPLETED
A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity
GlaxoSmithKline n=109
NCT01392300 COMPLETED
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Arm After a Stroke
Merz Pharmaceuticals GmbH n=317
NCT01464307 COMPLETED
Efficacy and Safety Study of Botulinum Toxin Type A Against Placebo to Treat Spasticity in the Leg After a Stroke
Merz Pharmaceuticals GmbH n=290
NCT01575054 COMPLETED
BOTOX® Treatment in Adult Patients With Post-Stroke Lower Limb Spasticity
Allergan n=468
NCT01945684 COMPLETED
A Randomized, Double Blind, Multi-center, Active Drug Controlled, Phase III Clinical Trial to Compare the Safety and Efficacy of DWP450 Versus Botox® in Treatment of Post Stroke Upper Limb Spasticity
Daewoong Pharmaceutical Co. LTD. n=197
NCT01915459 COMPLETED
Phase III Study of Botulax® to Treat Post Stroke Upper Limb Spasticity
Hugel n=186
NCT01051128 WITHDRAWN
Continuous Intrathecal Baclofen Infusion for Chronic Spasticity
Flowonix Medical
NCT02145689 WITHDRAWN
Long-Term Study of OnabotulinumtoxinA Treatment in Adult Patients With Upper Limb Spasticity
Allergan
NCT00819065 COMPLETED
Trial Comparing Two Commercial Formulations of Botulinum Toxin Type A in the Treatment of Spasticity
Hospital de Clinicas de Porto Alegre n=56
NCT04099667 TERMINATED
Efficacy and Safety Study of MYOBLOC® in the Treatment of Adult Lower Limb Spasticity
Solstice Neurosciences, LLC, a subsidiary of MDD US Operations, LLC n=40
Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only